STABLECOIN DEVELOPMENT CORP
SDEVNYSE AMERICANTrading Snapshot
- Day Range
- $3.00 β $3.10
- 52-Week Range
- $0.78 β $99.75
- Volume
- $1.83B
- Avg Volume
- $1.59B
- Shares Outstanding
- 50.5M
- Next Earnings
- Oct 31, 2026
Fundamentals Snapshot
- Annual Revenue
- $28M
- Last Q Revenue
- $2M
- P/E Ratio
- 0.2
- P/S Ratio
- 2.7x
- EPS (TTM)
- $-0.43
- Dividend Yield
- β
- Dilution (1yr)
- +495.7%
Why Investors Own SDEV
- βHigh-growth profile β revenue up +53.7% YoY with expanding US Equity exposure.
- βHealthy economics β 35% gross margin and 27% free-cash-flow margin.
- βNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
STABLECOIN DEVELOPMENT CORP
SDEVAbout STABLECOIN DEVELOPMENT CORP
Stablecoin Development Corp. specializes in manufacturing and distributing eye and skin health solutions that have undergone rigorous scientific development and proven efficacy in clinical settings. Their product portfolio features prominent brands such as Avenova, NeutroPhase, and DERMAdoctor. This enterprise was established on January 19, 2000, and its main office is situated in Emeryville, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Analyst Ratings
βLatest News & Updates
STABLECOIN DEVELOPMENT CORP tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
Analysts lift SDEV price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
STABLECOIN DEVELOPMENT CORP announces new agreement to expand its footprint
The move broadens the companyβs reach and could add incremental revenue over the next year.